Cognition in aging and neurodegenerative diseases reflects the net effect of multiple pathological, neuroplastic, and brain reserve processes. Penn's P30 Alzheimer's Disease Core Center (ADCC) is the foundation for many interactive clinical and basic research programs on AD and related disorders at Penn and beyond that investigate these processes. The Clinical Core's role is to support and promote this research to better characterize mechanisms of disease and resilience in patients and controls, to characterize the ways in which pathology clinically manifests in people over time, and to investigate ways to prevent or treat disease in order to maximize daily function and quality of life of older adults. The Clinical Core's base of operations is the Penn Memory Center (PMC), a multidepartmental clinical and clinical research outpatient center of the University of Pennsylvania Health System, where many of our research participants are recruited. We also have a longstanding research interest and commitment to an underserved Latino minority community through satellite recruitment in primary care practices in North Philadelphia and with the Education Core, we are expanding our outreach in the African American communities of West Philadelphia. The Clinical Core characterizes a longitudinal cohort of people with normal and abnormal brain aging who participate in our ADCC and its affiliated research programs by: a) applying standardized rating scales to measure past and current medical, cognitive, neurological, behavioral, and functional status, b) conducting and monitoring the clinical utility of neuroimaging studies and molecular-biochemical biomarkers for diagnosis, prognosis, and outcome c) establishing reliable and accurate consensus diagnosis, d) meticulously collecting and handling biospecimens, and e) recruiting and enrolling into affiliated research studies. The Clinical Core is the nexus for almost all of the clinical research conducted on AD and related disorders at Penn. It performs critical functions to support the mission of the Penn ADCC to increase the quality and quantity of AD-relevant research at Penn and beyond. Accordingly, it will continue to implement the following three aims:
Aim 1 : To identify, assess, and longitudinally evaluate patients from the earliest symptomatic stage of neurodegenerative dementia as well as individuals with normal cognition, gathering clinical data compliant with the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS), in addition to neuroimaging data, and biological material, including cerebrospinal fluid (CSF), blood, DNA and brain tissue.
Aim 2 : To facilitate the participation of individuals evaluated by the Clinical Core in collaborative research studies, including those of the Alzheimer's Disease Cooperative Study (ADCS) and the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Aim 3 : To integrate the collection and management of data and biological samples with the other cores in a manner that facilitates collaborative studies and sample sharing among the ADCs and other qualified investigators.
AD and other related dementias are among the most common, feared, and costly conditions in later life. The Clinical Core of the Penn ADCC plays a central role in the assessment, diagnosis, research recruitment and longitudinal management of older adults with cognitive decline as well as their comparison to research participants with successful cognitive aging. Through a better understanding of healthy and diseased cognitive aging, we seek to improve the functioning and quality of life of older adults.
|Cousins, Katheryn A Q; Ash, Sharon; Irwin, David J et al. (2017) Dissociable substrates underlie the production of abstract and concrete nouns. Brain Lang 165:45-54|
|Henderson, Michael X; Chung, Charlotte Hiu-Yan; Riddle, Dawn M et al. (2017) Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies. J Neurosci 37:5870-5884|
|LoBue, Christian; Wadsworth, Hannah; Wilmoth, Kristin et al. (2017) Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease. Clin Neuropsychol 31:85-98|
|Brown, Christopher A; Johnson, Nathan F; Anderson-Mooney, Amelia J et al. (2017) Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. Neuroimage Clin 13:106-115|
|Bell, S P; Liu, D; Samuels, L R et al. (2017) Late-Life Body Mass Index, Rapid Weight Loss, Apolipoprotein E ?4 and the Risk of Cognitive Decline and Incident Dementia. J Nutr Health Aging 21:1259-1267|
|Phillips, Jeffrey S; Da Re, Fulvio; Dratch, Laynie et al. (2017) Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiol Aging 63:75-87|
|Monsell, Sarah E; Mock, Charles; Fardo, David W et al. (2017) Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. Alzheimer Dis Assoc Disord 31:232-238|
|Chapuis, Julien; Flaig, Amandine; Grenier-Boley, Benjamin et al. (2017) Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol 133:955-966|
|Lee, Edward B; Porta, Sílvia; Michael Baer, G et al. (2017) Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 134:65-78|
|Irwin, David J; Grossman, Murray; Weintraub, Daniel et al. (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16:55-65|
Showing the most recent 10 out of 586 publications